CVS will pay $38M to settle drug-switching claims

CVS Caremark Corp. last week agreed to pay $37.8 million to the U.S. government and states including Rhode Island, Massachusetts and Connecticut, to settle Medicaid drug-switching claims related to its handling of ranitidine, the generic form of the heartburn medicine Zantac. The settlement concludes investigations by the U.S. Department of Justice and 23 states into…

Want More Free?

To access 2 more articles, please log in or register for free.

Registered users get access to a limited number of free articles every month.

Register Now

Already registered? Login to access more free articles.

Purchase NowWant to share this story? Click Here to purchase a link that allows anyone to read it on any device whether or not they are a subscriber.

- Advertisement -